WO2026086805 - PCSK9 AND HMG-COA BICYCLIC COMPOUND, AND PREPARATION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/086805
Publication Date
30.04.2026
International Application No.
PCT/CN2025/129130
International Filing Date
22.10.2025
Title **
[English]
PCSK9 AND HMG-COA BICYCLIC COMPOUND, AND PREPARATION AND USE THEREOF
[French]
COMPOSÉ BICYCLIQUE DE PCSK9 ET HMG-COA, SA PRÉPARATION ET SON UTILISATION
[Chinese]
PCSK9和HMG-CoA双环化合物及基制备与应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
LAI, Yingjie
LI, Zhongle
XIAO, Ying
LI, Hongchao
QING, Zhineng
QI, Yinliang
WU, Kang
ZENG, Junnan
Priority Data
202411491336.2
23.10.2024
CN
202411808677.8
09.12.2024
CN
202510224724.2
26.02.2025
CN
202510480593.4
16.04.2025
CN
202510652400.9
20.05.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1935 | |
| EPO | Filing, Examination, Granting | 11786 | |
| Japan | Filing, Examination, Granting | 2093 | |
| South Korea | Filing, Examination, Granting | 2135 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,689
Contact Us
Abstract[English]
The present invention relates to the technical field of chemical drugs, and in particular to a PCSK9 and HMG-CoA bicyclic compound, or an isomer, racemate or pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof. The present invention further relates to a use of the PCSK9 and HMG-CoA bicyclic compound as a PCSK9 inhibitor and/or an HMG-CoA reductase inhibitor, and a method for the treatment of multiple specific diseases or conditions using the PCSK9 and HMG-CoA bicyclic compound.[French]
La présente invention se rapporte au domaine technique des médicaments chimiques, et concerne en particulier un composé bicyclique de PCSK9 et HMG-CoA, ou un isomère, un racémate ou un sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation et son utilisation. La présente invention concerne en outre une utilisation du composé bicyclique de PCSK9 et HMG-CoA en tant qu'inhibiteur de PCSK9 et/ou un inhibiteur de HMG-CoA réductase, et une méthode de traitement de multiples maladies ou affections spécifiques faisant appel au composé bicyclique de PCSK9 et HMG-CoA.[Chinese]
本发明属于化学药物技术领域，涉及PCSK9和HMG-CoA双环化合物，或其异构体、或其消旋体、或其可药用的盐，及其制备方法与应用。作为一种PCSK9抑制剂和/或HMG-CoA还原酶抑制剂，以及使用其治疗多种特定疾病或病状的方法。